MedTrace Logo

High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium

NCT05845424 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2025-01-14

No results posted yet for this study

Summary

The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.

Conditions

  • Coronary Artery Calcification
  • Metabolic Syndrome
  • Dyslipidemias

Interventions

DRUG

Guideline directed statin therapy

At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk

DRUG

High intensity statin plus ezetimibe therapy

Rosuvastatin 20 mg + Ezetimibe 10 mg

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Seung-Hyuk Choi · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-03
Primary Completion
2029-06-30
Completion
2030-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845424 on ClinicalTrials.gov